VSTM
Verastem·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Beats Expectation
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VSTM
Verastem, Inc.
A company that developing small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics
117 Kendrick Street
, Suite 500
, Needham
, Massachusetts 02494
--
Verastem, Inc., was incorporated as a Delaware corporation on August 4, 2010. The company is a late-stage biopharmaceutical company that is conducting registration-oriented trials to advance new drugs for patients battling cancer. The company's pipeline focuses on novel anticancer agents that inhibit key signaling pathways in cancer that promote cancer cell survival and tumor growth, specifically RAF/MEK inhibition and FAK inhibition.
Company Financials
EPS
VSTM has released its 2025 Q3 earnings. EPS was reported at -1.35, versus the expected -0.61, missing expectations. The chart below visualizes how VSTM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VSTM has released its 2025 Q3 earnings report, with revenue of 11.24M, reflecting a YoY change of NaN%, and net profit of -98.52M, showing a YoY change of -311.06%. The Sankey diagram below clearly presents VSTM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
